Generic pharmaceutical company Lannett Company Inc (NYSE:LCI) stated on Monday that it recorded a net loss of USD7.6m (USD0.20 per share) for its fiscal fourth quarter ended 30 June 2019.
This is an improvement in earnings when compared with a higher net loss of USD11.4m (USD0.30 per share) for the fiscal 2018 fourth quarter.
GAAP net sales of USD133.8m were recorded for its fiscal fourth quarter ended 30 June 2019, down over USD170.9m for the fourth quarter of fiscal 2018.
Research and development (R&D) expenses of USD9.4m were reported for its fiscal fourth quarter ended 30 June 2019, a rise versus R&D of USD8.3m for the fiscal 2018 fourth quarter.
Biocon's first US manufacturing facility inaugurated in Cranbury, New Jersey
Amneal's risperidone extended-release injectable suspension approved by US FDA
First FDA acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Viatris' generic iron sucrose injection gains US FDA approval
Newbury Pharmaceuticals gains Finnish approval for generic melatonin
CivicaScript to distribute biosimilar for chronic inflammatory conditions
Mallinckrodt and Endo complete merger
Zenara Pharma's Sertraline Hydrochloride Capsules generic receives US FDA approval
Mallinckrodt receives Irish High Court ruling to combine with Endo Inc
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CivicaScript introduces low-cost multiple sclerosis treatment
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Glenmark Therapeutics launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)